Loss-of-function METTL14 mutations in endometrial cancer. Sequencing studies have found that the METTL14 subunit of the core m 6 A methyltransferase complex is frequently mutated N 6 -methyladenosine (m 6 A) messenger RNA methylation is a gene regulatory mechanism affecting cell differentiation and proliferation in development and cancer. To study the roles of m 6 A mRNA methylation in cell proliferation and tumorigenicity, we investigated human endometrial cancer in which a hotspot R298P mutation is present in a key component of the methyltransferase complex (METTL14). We found that about 70% of endometrial tumours exhibit reductions in m 6 A methylation that are probably due to either this METTL14 mutation or reduced expression of METTL3, another component of the methyltransferase complex. These changes lead to increased proliferation and tumorigenicity of endometrial cancer cells, likely through activation of the AKT pathway. Reductions in m 6 A methylation lead to decreased expression of the negative AKT regulator PHLPP2 and increased expression of the positive AKT regulator mTORC2. Together, these results reveal reduced m 6 A mRNA methylation as an oncogenic mechanism in endometrial cancer and identify m 6 A methylation as a regulator of AKT signalling.
N 6 -methyladenosine (m 6 A) is the most prevalent messenger RNA modification in humans 1, 2 . This modification is reversible 3 , and its biological effects are mostly mediated through 'writer' , 'eraser' and 'reader' proteins 1, 2 . A writer complex, consisting of a core METTL3-METTL14 m 6 A methyltransferase along with regulatory subunits [4] [5] [6] [7] [8] , catalyses the m 6 A methylation of mRNA. At least two eraser enzymes, FTO and ALKBH5, mediate the reversal of this methylation 3, 9 . m 6 A methylated transcripts are recognized by reader proteins that regulate pre-mRNA processing [10] [11] [12] [13] [14] , translation [15] [16] [17] [18] [19] and degradation 10, 19, 20 . m 6 A-dependent mRNA regulation is essential in mammals 21 , and defects in m 6 A methylation affect diverse biological processes 1, 2 . In particular, m 6 A mRNA methylation regulates the self-renewal and differentiation of stem cells by affecting mRNA turnover during cell differentiation and plays critical roles in transcriptome switching during embryonic development 8, [21] [22] [23] . Consistent with these roles, m 6 A mRNA methylation is emerging as a pathway affecting cancer initiation and progression in a variety of cancers [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . m 6 A mRNA methylation affects the growth and proliferation of stem cells and cancer cells 8, 21, 22, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . However, how m 6 A methylation affects cell growth and which underlying pathways and mechanisms mediate these changes are still not fully elucidated. Herein, we study this question in endometrial cancer, where sequencing studies have identified frequent mutation of the m 6 A methyltransferase subunit METTL14 (ref. 36 ). We found that about 70% of endometrial tumours exhibit reduced m 6 A methylation when compared with matched, normal endometrium. These reductions in m 6 A methylation were probably caused by either mutation of METTL14 or reduced expression of the METTL3 methyltransferase. Reducing m 6 A mRNA levels in endometrial cancer cells through either METTL14 mutation or METTL3 downregulation could enhance cell proliferation and tumorigenicity in vitro and in vivo. m 6 A-seq characterization of endometrial cancer patient tumours and cell lines revealed that reduced m 6 A mRNA methylation could promote cell proliferation by altering the expression of key enzymes that affect the AKT signalling pathway. Inhibition of AKT activation reversed the increased proliferation caused by reduced m 6 A methylation. Together, these results characterize a somatic mutation of the m 6 A methylation machinery as an important factor promoting cancer progression, reveal that reduced m 6 A mRNA methylation is most likely an oncogenic mechanism underlying a large portion of endometrial cancers and identify m 6 A methylation as a regulator of the AKT pathway and cell growth.
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NATuRE CELL BiOLOgy in endometrial tumours 36 , but the relevance of these mutations and of m 6 A mRNA methylation to the disease has not yet been established. The predominant mutation occurs at position 298 of METTL14, is more prevalent than other mutations in endometrial tumours and occurs in about 1.5% of endometrial cancer patients 36 . Crystal structures of the METTL3-METTL14 complex reveal that the Arg 298 residue lies in the putative RNA-binding groove at the interface between the two subunits [37] [38] [39] . Consistent with previous observations 38 , we found that the R298P hotspot mutation significantly reduced the RNA methylation activity of the writer complex in vitro (Fig. 1a ). Whereas overexpression of wild-type METTL14 promoted m 6 A methylation of cellular poly(A) RNAs in HEC-1-A endometrial cancer cells, the mutant METTL14 appeared inactive upon overexpression (Fig. 1b ). While overexpression of wildtype METTL14 decreased cell proliferation, overexpression of the mutant had no noticeable effect on cell proliferation (Fig. 1c) , suggesting that the METTL14 mutation is probably a loss-of-function allele that shows no evidence of further dominant negative effects on m 6 A methylation or cell proliferation.
To examine the consequence of the mutation in tumour tissue, we identified three endometrial tumour samples bearing the METTL14(R298P) mutation and purified mRNA from these tumours as well as from adjacent benign endometrial tissues (Methods). Compared with mRNA from the wild-type adjacent The methyltransferase activity of the METTL3-METTL14 complex containing either the METTL14(R298P) mutant (mu) or wild-type (wt) METTL14 was determined by measuring the d 3 -m 6 A/G ratio by liquid chromatography-tandem mass spectrometry (LC-MS/MS) after incubation of the methyltransferase complex with RNA probe. We independently purified two batches of protein and carried out two independent trials per protein preparation for a total of n = 4 independent trials. b, LC-MS/MS quantification of the m 6 A/A ratio in poly(A) RNA isolated from HEC-1-A cells overexpressing wild-type METTL14, mutant METTL14 or empty vector control. n = 3 biological replicates. c, Cell proliferation of HEC-1-A cells was measured by MTS assay after transfection with the indicated reagents. n = 3 biological replicates. For a-c, error bars indicate mean ± s.e.m. d, LC-MS/MS quantification of the m 6 A/A ratio in poly(A) RNA isolated from three endometrial tumours with a METTL14(R298P) mutation and adjacent normal endometrium. The bar shows the mean from n = 3 technical replicates per patient. e, Box plot of the relative m 6 A levels in poly(A) RNA isolated from endometrial tumour tissues versus tumour-adjacent tissues, n = 38 tumour-normal pairs. f, Box plot of the expression levels of METTL3, METTL14, FTO, ALKBH5, YTHDF1 and YTHDF2 in tumour tissues relative to tumour-adjacent tissues, n = 22 tumour-normal pairs for METTL14 and FTO, and n = 38 tumour-normal pairs for the others. For a-c, e and f, the P-values were determined by two-tailed t-test. See methods for box-plot characteristics. g, Scatter plot showing the correlation of m 6 A methylation level with the expression of METTL3. The linear best fit line is shown in red. The Pearson correlation coefficient (r) and P-value (P) from a two-tailed t-test of r = 0 are shown, n = 38 tumour-normal pairs. h, Left: IHC staining of endometrial tissue microarray cores for METTL3. Right: Quantification of IHC staining in normal endometrium (n = 10 cores) and epithelial endometrial tumours (n = 30 cores). Staining was assessed using automated software 51 and scored on a scale of 0 (no staining) to 3 (high staining). Scale bars, 50 μ m. P-value determined by χ 2 -test. 
Fig. 2 | Reduced m 6 A methylation increases cell proliferation, anchorage-independent growth, migration and in vivo tumour growth. a, LC-MS/MS
quantification of the m 6 A/A ratio in poly(A) RNA from the indicated HEC-1-A cell lines. b, Cell proliferation measured by MTS assay of wild-type HEC-1-A cells (WT), METTL14 +/− knockout cells, and knockout cells rescued by stable transfection of wild-type METTL14 (wt) or METTL14(R298P) (mu). Cell numbers were normalized to the MTS signal about 5 h after cell seeding. c-e, Anchorage-independent cell growth (c), colony formation (d) and cell migration in a wound-healing experiment (e) were assessed for wild-type HEC-1-A cells, METTL14 +/− knockout cells, and knockout cells rescued with wild-type or mutant METL14. f, LC-MS/MS quantification of the m 6 A/A ratio in poly(A) RNA from the indicated HEC-1-A cell lines. (g) Cell proliferation measured by MTS assay of HEC-1-A cells stably expressing control shRNA (shControl) versus shRNA targeting METTL3 (shMETTL3. 15, shMETTL3.18) . Cell numbers were normalized to the MTS signal about 5 h after cell seeding. h-j, Anchorage-independent cell growth (h), colony formation (i) and cell migration in a wound-healing assay (j) were assessed for HEC-1-A cells stably expressing control shRNA or shRNA targeting METTL3. For a-j, n = 3 biological replicates. Error bars indicate mean ± s.e.m. P-values determined by two-tailed t-test. k-m, Wild-type HEC-1-A cells and METTL14 +/− knockout cells (k), knockout cells rescued with wild-type or mutant METTL14 (l) and HEC-1-A cells with shRNA knockdown of METTL3 or control shRNA (m) were injected into mice. The total tumour weight (left) and the total number of tumours (right) were recorded after 2-3 weeks. For k, n = 8 and for l and m n = 10 mice per group. Error bars indicate mean ± s.e.m. P-values determined by two-tailed t-test.
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NATuRE CELL BiOLOgy normal tissues, mRNA from the three mutant tumours had reduced overall m 6 A methylation (P = 0.04, paired two-tailed t-test), suggesting that the METTL14(R298P) mutation inhibits m 6 A mRNA methylation in tumours ( Fig. 1d ).
Endometrial cancer is associated with low levels of m 6 A mRNA methylation. Intriguingly, about 70% of all tumours we examined (including a majority of tumours with wild-type METTL14) exhibited reduced total m 6 A mRNA methylation when compared with adjacent, normal endometrial tissues ( Fig. 1e ). Thus, we hypothesized that endometrial cancer could be more broadly associated with the altered expression of factors that regulate m 6 A mRNA methylation. To test this hypothesis, we evaluated the expression of m 6 A writers, erasers and readers in tumour and adjacent normal endometrial tissues by quantitative PCR with reverse transcription (RT-qPCR) ( Fig. 1f and Supplementary Fig. 1a ). We found that a majority of endometrial cancers exhibited significantly reduced expression of the METTL3 m 6 A methyltransferase when compared with adjacent normal tissues. Decreased METTL3 expression correlates with reduced m 6 A methylation in these tumour tissues ( Fig.  1g ). Immunohistochemistry of a tissue microarray with both normal endometrium and epithelial endometrial cancer specimens revealed a significant decrease in METTL3 expression in tumour tissue at the protein level ( Fig. 1h ). METTL14 mutation and decreased METTL3 expression appear to be mutually exclusive, as all three of the tumours with the METTL14 mutation had normal expression of METTL3 relative to adjacent normal tissues. Analysis of the TCGA endometrial cancer dataset did not reveal any significant correla-tion between the mutation status of frequently mutated genes in endometrial cancer and low METTL3 expression ( Supplementary  Fig. 1b ). Taken together, these results suggest that a large proportion of human endometrial tumours are characterized by reduced m 6 A mRNA methylation, through either METTL14 loss-of-function mutation or decreased METTL3 expression.
Reduced m 6 A methylation promotes endometrial cancer cell proliferation.
Considering that about 20-30% of all mRNAs are methylated inside most mammalian cells 10, 40 , the observed global decrease in m 6 A mRNA methylation could have significant effects on cellular physiology, in particular if the methylation of key transcripts is affected [25] [26] [27] [28] [29] [30] [31] . Analysis of patients from the TCGA dataset showed that tumours with low METTL3 expression are associated with a slight increase in mortality, though this difference is not statistically significant ( Supplementary Fig. 1c ). However, analysis of other related cancer types (high-grade serous ovarian cancer 41 and pancreatic adenocarcinoma 42 ) found statistically significant increases in mortality associated with decreased METTL3 expression ( Supplementary Fig. 1c ). Therefore, we next examined whether the reduced m 6 A methylation observed in the human endometrial tumour tissue samples affects functions associated with tumour progression in human tumour cells. To investigate the effects of METTL14 loss of function in endometrial cancer cell lines, we used CRISPR technology to delete METTL14 from HEC-1-A cells. We obtained clones exhibiting only heterozygous knockout of METTL14, reflecting the essential nature of the writer complex in mammals. Heterozygous knockout was confirmed by western blot 
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( Supplementary Fig. 2a ) and sequencing (Methods). As expected, the METTL14 +/cells exhibited reduced m 6 A mRNA methylation, and the reductions in m 6 A methylation are similar to those observed in the tumour samples ( Fig. 2a ). Consistent with a role for METTL14 loss of function in endometrial cancer, heterozygous knockout of METTL14 increased cell proliferation, anchorageindependent growth, colony formation, cell migration and invasion ( Fig. 2b-e and Supplementary Fig. 2b ). The reduced m 6 A methylation and changes to the cancer cell physiology could be partially rescued by stable expression of wild-type METTL14 but not mutant METTL14 ( Fig. 2a -e and Supplementary Fig. 2b ). We observed similar effects after short hairpin RNA (shRNA) knockdown of METTL14 versus control shRNA ( Supplementary Fig. 2a , c-h).
To determine the effects of reduced METTL3 expression in endometrial cancer cells, METTL3 was stably knocked down by shRNA in HEC-1-A cells using two different shRNA sequences ( Supplementary Fig. 2i ). Similar to the expression of mutant METTL14, knockdown of METTL3 decreased the overall levels of m 6 A mRNA methylation and promoted cell proliferation, anchorage-independent growth, colony formation, migration and invasion relative to control cells ( Fig. 2f-j and Supplementary Fig. 2j ).
To corroborate the observations that reduced m 6 A methylation stimulates aggressive phenotypes of cancer cells in vitro, we investigated the roles of METTL14 and METTL3 in tumour growth in vivo. Wild-type HEC-1-A cells and METTL14 +/− knockout cells were injected into the peritoneal cavity of nude mice, and tumour numbers and total mass were evaluated after 2-3 weeks. METTL14 +/− knockout cells showed dramatically larger tumours and an increased number of metastases relative to wild-type HEC-1-A cells ( Fig. 2k ). Similar trends were observed when METTL14 +/− cells rescued with wild-type and mutant METTL14 were compared ( Fig. 2l ) and when comparing METTL3 knockdown HEC-1-A cells with control ( Fig. 2m ). Taken together, these results reveal that the reduced m 6 A mRNA methylation observed in the patient endometrial tumour samples, whether induced by METTL14(R298P) mutation or reduced METTL3 expression, could promote the tumorigenicity of endometrial cancer cells and might play critical roles in the progression of endometrial cancer. m 6 A-seq identifies transcripts with altered methylation in endometrial tumours. Next, we performed m 6 A-seq analysis of human endometrial tumour tissues versus normal, tumour-adjacent tissues from five patients. All five tumours exhibited low total m 6 A levels; one carried the METTL14 mutation and the four others exhibited low METTL3 expression ( Supplementary Fig. 3a,b ). Consistent with previous m 6 A-seq results 10, 40 , the m 6 A peaks we identified were enriched near the start and stop codons and were characterized by the canonical GGACU motif ( Supplementary Fig. 3c,d ). In the normal tissue samples, we identified on average about 20,000 significant m 6 A peaks (false discovery rate < 0.05) in about 8,000 transcripts, and the identified transcripts show good agreement between samples ( Supplementary Fig. 3e ). Among the m 6 A peaks detected in 
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NATuRE CELL BiOLOgy over half of the patient samples, we found that their m 6 A mRNA methylation was reduced globally in the tumour compartment compared with adjacent, normal control tissues (Fig. 3a) . The transcripts exhibiting decreased m 6 A methylation were fairly consistent between tissue samples ( Supplementary Fig. 3f ), and the transcripts showing decreased m 6 A methylation in at least two samples were enriched for gene ontology (GO) terms related to cell migration, proliferation, growth, adhesion and cell death (Fig. 3b ). m 6 A-seq experiments revealed similar global decreases in m 6 A methylation and GO term enrichment in HEC-1-A METTL3 knockdown and mutant METTL14 cells relative to controls ( Supplementary Fig. 3e -g and Supplementary Fig. 4a ). m 6 A methylation regulates activation of AKT. The GO term analysis identified the AKT/protein kinase B signalling pathway as being significantly altered by reduced m 6 A methylation in both the patient samples (P = 1.51 × 10 -8 ) and the endometrial cancer cell lines (P = 1.02 × 10 -8 ) ( Fig. 3b and Supplementary Fig. 4a ). Because the AKT signalling pathway promotes cell survival and growth and is frequently activated through oncogenic mutations in endometrial cancer and other cancers 43-45 , we hypothesized that reduced m 6 A methylation might promote tumour growth through activation of the AKT pathway. Indeed, many of the genes involved in the AKT pathway showed reduced m 6 A methylation in tumours when compared with tumour-adjacent tissues (Fig. 3c,d ). We evaluated a subset of these transcripts in the mutant METTL14 and METTL3 knockdown cells by m 6 A immunoprecipitation (m 6 A-IP) followed by RT-qPCR, which confirmed their reduced m 6 A methylation ( Supplementary Fig. 4b-e ).
We next determined if reduced m 6 A methylation in endometrial cancer cells affects AKT signalling by investigating the phosphorylation status of AKT. Our METTL14 loss-of-function HEC-1-A cell lines (METTL14 +/− , mutant METTL14 rescue and shMETTL14) showed increased phosphorylation of AKT at Ser-473 when compared with the relevant control cell lines (wild-type HEC-1-A cells, wild-type METTL14 rescue and shControl, respectively) ( Fig. 4a ). Similar increases in AKT(S473) phosphorylation were seen in the METTL3 knockdown HEC-1-A cell lines relative to control knockdown cells (Fig. 4a ). In contrast, phosphorylation at Thr-308 and the total AKT protein expression remained unchanged (Fig. 4a ). To assess whether these changes in AKT phosphorylation stimulate AKT signalling, we assessed the phosphorylation status of downstream effectors of AKT (Fig. 4b ). Both FOXO1 and p27 showed increased phosphorylation in the METTL14 loss-of-function and Remaining mRNA after TI Articles NATuRE CELL BiOLOgy METTL3 knockdown cells relative to control. Two other AKT substrates, tuberin and PRAS40, showed no consistent changes in phosphorylation, congruent with previous reports that only a subset of AKT targets are affected by changes to Ser-473 phosphorylation without any difference in Thr-303 phosphorylation 46 . These results suggest that reducing m 6 A methylation activates the AKT pathway.
m 6 A methylation controls the expression of regulators of AKT activation.
To determine the mechanisms underlying increased AKT activation upon reduced m 6 A methylation, we examined PHLPP2, a phosphatase regulating AKT(S473) phosphorylation 47 , and mTORC2, a kinase that phosphorylates AKT(S473) 48 . Transcripts encoding PHLPP2 and three components of the mTORC2 complex (PRR5, PRR5L and mTOR) showed decreased m 6 A methylation in patient samples (Fig. 4c ). These transcripts also showed decreased m 6 A methylation in the METTL14 loss-offunction and METTL3 knockdown HEC-1-A cell lines (Fig. 4d ).
In these cell lines, we observed decreased expression of PHLPP2 protein, while its mRNA levels were not noticeably altered; in contrast, we observed increased mRNA expression of PRR5, PRR5L and mTOR in addition to increased protein levels of p-mTOR(S2481), a marker for mTORC2 49 (Fig. 4a,d) . These changes are consistent with increased AKT phosphorylation and activity. To investigate whether these changes in protein expression occur in tumour tissues, we performed immunohistochemical (IHC) staining in normal endometrium and endometrial tumours in a tissue microarray (Fig. 4e,f and Supplementary Fig 4g,h) . PHLPP2 was indeed downregulated in human endometrial tumours when compared with benign endometrial glands. We observed increased staining for PRR5, PRR5L and phospho-mTOR(S2481) in a subset of tumours, though the increases were not always statistically significant, suggesting that additional factors may be influencing mTORC2 expression in tumours when compared with our cell lines. We next explored the mechanism for how m 6 A methylation regulates the expression of PHLPP2 and mTORC2. Because m 6 A methylation appeared to promote the expression of PHLPP2, we hypothesized that PHLPP2 transcripts are targets of YTHDF1, the m 6 A reader protein that promotes translation of m 6 A methylated transcripts 16 . Consistent with this hypothesis, short interfering RNA (siRNA) knockdown of YTHDF1 in HEC-1-A cells decreased expression of PHLPP2 to a similar extent to knockdown of METTL3 (Fig. 5a ). These changes in PHLPP2 expression are due not to changes in the abundance of the PHLPP2 transcript but to the association of the PHLPP2 transcript with actively transcribing ribosomes (Fig. 5b,c and Supplementary Fig. 5b,c) . mTORC2, on the other hand, appeared to be downregulated by m 6 A methylation, suggesting that it is a target of YTHDF2, the m 6 A reader protein that promotes the decay of m 6 A methylated transcripts 20 . Consistent with this hypothesis, siRNA knockdown of YTHDF2 increased the abundance of the PRR5, PRR5L and mTOR transcripts and these transcripts showed decreased RNA decay rates upon knockdown of YTHDF2 (Fig. 5b,g-i) . Knockdown of YTHDF2 also resulted in higher protein levels of mTOR and p-mTOR(S2481) (Fig. 5a ). The effects of the reader proteins appeared to be specific to these sets of transcripts, as knockdown of YTHDF2 did not appreciably affect the expression or decay of PHLPP2 (Fig. 5a ,b,f), while knockdown of YTHDF1 did not appreciably affect the expression of mTOR or p-mTOR(S2481) or the association of PRR5, PRR5L or mTOR transcripts with ribosomes ( Fig. 5a and Supplementary Fig 5d-f) . The specificity for reader function probably occurs at the level of Supplementary Fig. 8 .
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RNA binding, as PHLPP2 transcripts interacted more strongly with YTHDF1 than YTHDF2, while PRR5, PRR5L and mTOR transcripts interacted more strongly with YTHDF2 than YTHDF1 (Fig. 5d,e ). To better understand the effects of m 6 A-mediated changes to PHLPP2 and mTORC2 expression on AKT activation, we examined the time course of AKT activation upon stimulation of HEC-1-A cells. Consistent with previous studies 47 , we observed transient phosphorylation of AKT in our knockdown control cells after epidermal growth factor (EGF) stimulation, which decreased after 0.5-1 h; however, in the METTL3 knockdown cell line, AKT activation persisted for much longer periods of time ( Supplementary Fig 6a) , consistent with decreased PHLPP2 expression. Similar results were observed for the wild-type METTL14 versus mutant METTL14 HEC-1-A cells ( Supplementary Fig. 6b ), though the kinetics of dephosphorylation were slower in the wild-type METTL14 cell line than in the knockdown control cell line, perhaps reflecting incomplete rescue of the HEC-1-A METTL14 +/− cells.
To confirm that our results extend beyond the HEC-1-A endometrial cancer cell line, we tested the effects of knockdown and overexpression of METTL3 and METTL14 in a second endometrial cancer cell line, RL95-2, as well as hTert-immortalized human endometrial stromal cells (T-HESCs), a normal non-transformed cell line, and found similar m 6 A-mediated changes to cell proliferation and AKT signalling ( Fig. 6 and Supplementary Fig. 6c-f ). Thus, decreased m 6 A methylation leads to diminished YTHDF1-promoted translation of PHLPP2, a negative regulator of AKT activation, and precludes the YTHDF2-promoted decay of mRNAs encoding the mTORC2 complex, a positive regulator of AKT. Altogether, these experiments reveal that reduced m 6 A mRNA methylation affects multiple AKT pathway components to stimulate AKT activation.
Increased AKT signalling mediates the effects of reduced m 6 A methylation on cell proliferation.
To determine if enhanced AKT activation underlies the increased proliferation observed upon reducing m 6 A methylation in endometrial cancer cells, we attempted to rescue this phenotype by either overexpressing PHLPP2 or by inhibiting mTORC2 through knockdown of the mTORC2-specific subunit gene RICTOR. Consistent with previous results 47,48 , overexpression of PHLPP2 ( Fig. 7a and Supplementary Fig. 7a ) and knockdown of RICTOR ( Fig. 7b and Supplementary Fig. 7b ) both decreased the levels of p-AKT(S473) in METTL3 knockdown, METTL14 mutant and METTL14 +/-HEC-1-A cells. PHLPP2 overexpression or RICTOR knockdown in METTL3 knockdown cells reduced cell proliferation rates, whereas these treatments had much smaller effects on the control cells (Fig. 7c) . Importantly, the cell proliferation rates of METTL3 knockdown cells after PHLPP2 overexpression or RICTOR knockdown were comparable to those of the control cells with normal METTL3 expression. Similar results were observed in the METTL14 mutant cells (Fig. 7c) as well as the METTL14 +/− cells ( Supplementary Fig. 7c,d) . Similar results were also seen when using a small-molecule inhibitor of the AKT enzyme ( Supplementary Fig. 7e,f) . Thus, genetic or pharmacologic 
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Discussion
The PI3K/AKT pathway plays important roles in a variety of biological processes, and dysfunctional AKT signalling contributes to diseases such as cancer, diabetes and autoimmune disease 44, 45 . In this study, we discovered that m 6 A mRNA methylation regulates the AKT pathway to control cell proliferation in endometrial cancer (Fig. 7d ). m 6 A methylation normally attenuates AKT activity in the endometrium by promoting the m 6 A-dependent translation of PHLPP2 and m 6 A-dependent degradation of transcripts encoding subunits of mTORC2. Upregulation of the PHLPP2 phosphatase and downregulation of the mTORC2 kinase both contribute to the inhibition of AKT activity by maintaining dephosphorylation of AKT(S473). Reduced m 6 A methylation disrupts the regulation of these transcripts, leading to decreased PHLPP2 expression, increased mTORC2 expression and increased AKT activity (Fig. 7d ). This mechanism probably contributes to a large fraction of endometrial tumours, as about 70% of tumour samples from endometrial cancer patients exhibited decreased m 6 A levels due to either decreased expression of METTL3 or loss-of-function mutation in METTL14. Using cultured endometrial cancer cells, we revealed that either mutation of METTL14 or downregulation of METTL3 reduced m 6 A mRNA methylation and enhanced proliferation and tumorigenicity. Our m 6 A-seq results from endometrial tumours and matched normal tissue along with our mechanistic studies in endometrial cancer cells reveal regulation of AKT activation as an important mediator of these changes to cell proliferation. Increased AKT activation is probably one of the main mediators of increased proliferation in cells with reduced m 6 A methylation, as inhibition of AKT is sufficient to rescue the changes in cell proliferation. However, we cannot rule out the involvement of other signalling pathways that could be altered directly or indirectly by changes to m 6 A methylation.
Because AKT is known to be an important regulator of cell proliferation, growth and survival in many cancers, these findings may be applicable beyond endometrial cancer to other cancers driven by increased AKT signalling. Other types of tumour could exploit aberrant RNA methylation to gain survival and growth advantages via AKT activation in addition to other proposed mechanisms [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Indeed, others have observed increased proliferation of stem cells and cancer cells with reduced m 6 A methylation 21, 22, [26] [27] [28] [29] [30] [31] , and while this paper was under review m 6 A methylation was reported to affect AKT activity in AML 33 , renal cell carcinoma 30 and T-cell differentiation 50 . Although our results suggest that decreased m 6 A methylation promotes tumorigenesis in the endometrium, other cancers are associated with high METTL3 expression and increased m 6 A methylation and could involve different mechanisms 24, [32] [33] [34] . Nevertheless, our results suggest that regulation of AKT activity through m 6 A methylation could be a general growth control mechanism that affects a range of other biological processes, which will be a new direction to explore in the future.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0174-4. 
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Methods
Cell lines, antibodies, siRNA knockdown and plasmid transfection. The HEC-1-A cells used in this study were purchased from ATCC (HTB-112) and grown in McCoy's 5A medium (Gibco, 16600) supplemented with 10% fetal bovine serum (FBS) (Gibco), and 1% penicillin-streptomycin (Gibco, 15140). Cells were free of mycoplasma (IDEXX STAT-Myco). The RL95-2 cells used in this study were purchased from ATCC (CRL-1671) and grown in DMEM:F-12 medium (Gibco, 11320) supplemented with 10% FBS, 0.005 mg ml −1 insulin (Sigma I0516), and 1% penicillin-streptomycin. The T-HESCs used in this study were purchased from ATCC (CRL-4003) and grown in DMEM:F-12 medium supplemented with 10% FBS, 1% ITS-premix (Corning 354352), 1 mM pyruvate (Gibco, 11360), 0.5 µ g ml −1 puromycin (Gibco, A11138) and 1% penicillin-streptomycin. The HEC-1-A cell line was authenticated with STR profiling (IDEXX Cell Check 9 Plus). The other cell lines were not authenticated. The primary antibodies were purchased from commercial sources, and information about the antibodies is given in Supplementary Table 1 . Actinomycin D (A9415) was purchased from Sigma, recombinant human EGF (PHG0311) was purchased from Thermo Fisher Scientific, MK-2206 (S1078) was purchased from Selleckchem and cyclohexamide (C7698) was purchased from Sigma.
The pcDNA3-HA-PHLPP2 plasmid was a gift from Alexandra Newton (Addgene plasmid no. 22403) 47 . Construction of the pcDNA3 plasmids for the expression of METTL3 and METTL14 in mammalian cells was as described previously 5 . All the siRNAs were ordered from QIAGEN. Allstars negative control siRNA (1027281) was used as siRNA control. Sequences for the other siRNAs are the following: METTL3, 5′ -CGTCAGTATCTTGGGCAAGTT-3′ ; YTHDF1, 5′ -CCGCGTCTAGTTGTTCATGAA-3′ ; YTHDF2, 5′ -AAGGACGTTCCCAATAGCCAA-3′ ; RICTOR, 5′ -TAGGTGCATTGACATACAACA-3′ . Transfection was achieved by using Lipofectamine RNAiMAX (Invitrogen) for siRNA, or Lipofectamine 2000 (Invitrogen) for the plasmids following manufacturer's protocols.
Patient sample collection, genomic DNA and RNA extraction, and genotyping.
All samples were obtained with informed consent under a protocol approved by the University of Chicago Institutional Review Board or the ethics committee of Zhongnan Hospital of Wuhan University, China. The study is compliant with all relevant ethical regulations regarding research involving human participants. Information about the patient sex, age and tumour characteristics are given in Supplementary Table 2 . For fresh tissues, endometrial tumour and adjacent normal endometrium were separately dissected at the time of surgery and immediately transferred to RNAlater (Thermo Fisher, AM7021). Tissues were homogenized in TRIzol reagent (Thermo Fisher, 15596026) with a Tissure-Tearor (BioSpec, 985-370). RNA and DNA were extracted following the manufacturer's instructions. For archival formalin-fixed, paraffin-embedded (FFPE) specimens, 10 × 10 µ m 2 scrolls were collected from FFPE blocks at the University of Chicago Human Tissue Resource Center. Samples were processed with a High Pure FFPE RNA Micro Kit (Roche, 04823125001) following the manufacturer's instructions. We used the TOPO-TA cloning kit (Invitrogen) to assess METTL14 mutation status in patient samples following the manufacturer's instructions. Primers used for subcloning are shown here: forward, 5′ -ATCCCAAAGATTCCGAGAAATGAGG-3′ ; reverse, 5′ -TGAGGTCCTACCTGGTCGAATTGT-3′ .
In vitro assay for m 6 A methyltransferase activity. The recombinant, Flag-tagged proteins METTL3, METTL14 and METTL14(R298P) were expressed in insect cells using the Bac-to-Bac baculovirus expression system and purified through Flag-tag IP according to a previously published procedure 5 . Protein purity was assessed by SDS-PAGE, and protein concentration was determined by ultraviolet absorbance at 280 nm.
We carried out an in vitro methyltransferase activity assay in a 50 µ l reaction mixture containing the following components: 0.15 nmol RNA probe, 0.15 nmol each fresh recombinant protein (METTL3 combination with an equimolar ratio of METTL14 or mutant METTL14), 0.8 mM d 3 -SAM, 80 mM KCl, 1.5 mM MgCl 2 , 0.2 U µ l −1 RNasin, 10 mM DTT, 4% glycerol and 15 mM HEPES (pH 7.9). The reaction was incubated for 12 h at 16 °C; RNA was recovered by phenol/chloroform (low-pH) extraction followed by ethanol precipitation and was digested by nuclease P1 and alkaline phosphatase for LC-MS/MS detection. The nucleosides were quantified by using the nucleoside-to-base ion mass transitions of 285 to 153 (d 3 -m 6 A) and 284 to 152 (G).
Construction of the stable cell lines.
To construct the METTL14 mutant cell line, we first used the CRISPR-Cas9 genome editing system from IDT to generate a METTL14 +/− cell line in HEC-1-A cells following the manufacturer's protocols. The guide RNA sequencing targeting METTL14 was 5′ -GCTCCCGGATCTCCTGCAAGCGG-3′ . Heterozygous METTL14 knockout cells were identified by western blotting for METTL14 and targeted Sanger sequencing. Sanger sequencing identified a 16-nucleotide deletion removing sequences encoding amino acids M1 to Q6, eliminating the start codon. Next, we transfected the METTL14 +/− cell lines with a PiggyBac Transposon System (SBI) encoding Flag-tagged wild-type METTL14 or METTL14(R298P). Stable transformants were selected with 1 µ g ml −1 puromycin and confirmed by western blotting for the Flag tag and METTL14.
To construct the METTL3 knockdown and control cell lines, we used the TRC lentiviral human shRNA system encoding a control shRNA or a shRNAs targeting METTL3 (RHS4533-EG56339, Dharmacon). Lentivirus was generated by transfection of 293T cells with shRNA constructs, VSV-G (Addgene, 8454) and gag/pol (pCMVΔ R8.2; Addgene, 8455) vectors 53 . Viral supernatants were collected at 48 and 72 h post-transfection, filtered and added to target cells for 4 h. Stable transformants were selected with 1 µ g ml −1 puromycin and confirmed by immunoblotting for METTL3.
RNA isolation. Total RNA was isolated with TRIzol reagent (Invitrogen). mRNA was extracted from the total RNA using a Dynabeads® mRNA purification kit (Invitrogen), followed by removal of contaminating rRNA with a RiboMinus transcriptome isolation kit (Invitrogen). mRNA concentration was measured by ultraviolet absorbance at 260 nm.
Total RNA samples used for RT-qPCR were isolated by using an RNeasy kit (Qiagen) with an additional on-column DNase-I digestion step.
RT-qPCR.
RT-qPCR was used to assess the relative abundance of mRNA. Total RNA or purified mRNA was reverse transcribed with SuperScript II reverse transcriptase (Invitrogen) using poly(dA) primers to obtain complementary DNA. qPCR was carried out by using SYBR Premix Ex Taq II (Takara). GAPDH (for mRNA expression level) and HPRT1 (for mRNA stability and m 6 A-IP) were used as internal controls. Primers used for RT-qPCR are the following:
METTL3_For Relative changes in expression were calculated using the Δ Δ C t method. LSBio LS-C144364-50) and phospho-mTOR-Ser2448 (1:100 dilution; Cell Signaling 49F9), heat-mediated antigen retrieval was carried out with 10 mM sodium citrate, 0.05% Tween 20, pH 6; for PHLPP2 (1:100; Abcam ab71973), antigen retrieval was carried out with 10 mM Tris base, 1 mM EDTA, 0.05% Tween 20, pH 9. Slides were processed with a VECTASTAIN Elite ABC HRP kit and DAB substrate kit (Vector Laboratories). Slides were counterstained with haematoxylin and dehydrated through graded alcohols and xylene. A total of 10 normal and 30 tumour samples had sufficient tissue for unambiguous analyses; all analyses were limited to the epithelial component of both normal and tumour samples. Images were processed with the ImageJ plugin IHC Profiler using the author's recommendations 51 . All tissues were assigned a score based on staining intensity in the epithelial compartment (0, no staining; 1, low positive; 2, positive; 3, high positive). The percentage of cells that were stained positive or negative was consistently uniform throughout the cores. m 6 A-seq. Total RNA was isolated from patient samples or HEC-1-A stable cell lines. Polyadenylated RNA was further enriched from total RNA using a Dynabeads® mRNA purification kit (Invitrogen). RNA fragmentation, m 6 A-IP and library preparation were carried out according to previously published protocols 10 . Sequencing was carried out at the University of Chicago Genomics Facility on an Illumina HiSeq2500 machine in single-read mode with 50 base pairs per read. m 6 A-seq data analyses. m 6 A-seq data were analysed according to the protocol described in ref. 57 . Briefly, TopHat2 (version 2.2.1) with Bowtie1 support 58, 59 was run to align the sequence reads to reference genome and transcriptome (hg19). Then the exomePeak R/Bioconductor package (version 3.7) 57 was used to find m 6 A peaks. Significant peaks with false discovery rate less than 0.05 were annotated to the RefSeq database (hg19). Sequence motifs were identified using Homer (version 4.9) 60 , and DAVID (version 6.8) was used to carry out GO term enrichment analysis 61 . Gene expression was calculated with Cufflinks (version 2.2.1) using the sequencing reads from input samples 62 . Cuffdiff was used to find the differentially expressed genes 63 . To assess global changes to m 6 A methylation, we identified all m 6 A peaks showing significant enrichment in at least half of the normal tissue samples, and enrichment values were averaged over all tumour or normal samples. Annotations for the PI3K/Akt pathway were taken from the KEGG Database 52 .
LC-MS/MS quantification of m 6 A in poly(
Measurement of RNA lifetime. HEC-1-A cells were seeded in 10 cm plates at 50% confluency. After 24 h, each 10 cm plate was re-seeded into three 6 cm plates. After 48 h, actinomycin D was added to 5 mg ml −1 6 h, 3 h and 0 h before trypsinization and collection. The total RNA was purified using an RNeasy kit with an additional DNase-I digestion step on the column. RNA quantities were determined by RT-qPCR. The degradation rate of RNA (k) was estimated by plotting N t /N 0 against time and fitting to the following equation:
where t is the transcription inhibition time, k is the degradation rate, and N t and N 0 are the RNA quantities at time t and time 0. The RNA lifetime (t 1/2 ) can be calculated from the degradation rate as follows:
= t k ln 2 1 2 Quantification of mRNA methylation with m 6 A-IP and RT-qPCR. We carried out m 6 A-IP enrichment followed by RT-qPCR to quantify the changes to m 6 A methylation of a certain target gene. 3 µ g purified cytosol mRNA extracted from the HEC-1-A stable cells was incubated with 5 µ g m 6 A antibody for 4 h at 4 ℃, then pulled down by protein A Dynabeads (Invitrogen) for 2 h at 4 ℃. RNA was extracted from the bead and flow-through fractions by acid phenol/chloroform extraction, then subjected to RT-qPCR. The HPRT1 gene was used as a reference gene when carrying out qPCR. For each gene, the Δ C t of input (Δ i), IP (Δ e) and flow-through (Δ d) were calculated relative to the reference. Given the set of equations
where E a and R a are the expression and methylation ratios of the gene of interest, and E r and R r are the expression and methylation ratios of the reference gene, we can solve for R a to obtain the following expression:
Polysome profiling. HEC-1-A cells were subjected to siRNA knockdown for 48 h and treated with cycloheximide at 100 µ g ml −1 for 7 min before collection. Cells were pelleted, lysed on ice in lysis buffer (20 mM HEPES pH 7.6, 100 mM KCl, 5 mM MgCl 2 , 1% Triton X-100, 100 µ g ml −1 cycloheximide, supplemented with protease inhibitor and RNase inhibitor) then centrifuged. The supernatant (~1.2 ml) was collected and loaded onto a 10/50% (w/v) sucrose gradient prepared in a lysis buffer without Triton X-100. The gradients were centrifuged at 4 °C for 3 h at 27,500 rpm (Beckman, rotor SW28). The sample was then fractioned and analysed using a Gradient Station (BioCamp) equipped with an ECONO UV monitor (BioRad) and fraction collector (FC203B, Gilson). The fractions were mixed with TRIzol reagent for purification of total RNA, which was analysed by RT-PCR. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
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Data collection
Cell images were collected with with a Nikon Eclipse Ti2 with NIS Elements Imaging Software (Version 5.02).
Data analysis
Images analyzed with ImageJ (Version 1.51i). IHC data was analyzed using the IHC Profiler ImageJ plugin (no version number given). Tophat2 (version 2.1.1), exomePeak R/Bioconductor package (version 3.7), Homer (version 4.9) , DAVID (version 6.8), and Cufflinks (version 2.2.1) were used to analyze the RNA-seq and m6A-seq data.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The RNA-seq and m6A-seq data generated by this study have been deposited in the GEO database under the accession number GSE93911. A summary of the m6A
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peaks identified by the m6A-seq experiments in the patient samples and cell lines can be found in Supplementary Tables 3 and 4 . The human data for high grade serous ovarian cancer and pancreatic adenocarcinoma, as well as some data for endometrial cancer, were derived from the TCGA Research Network: http:// cancergenome.nih.gov/. Source data for Figs 1-7 and Supplementary Figs 1-7 are provided in Supplementary Table 5 . Unprocessed immunoblot scans are presented in Supplementary Fig. 8 . All other data supporting the findings of this study are available from the corresponding author on reasonable request.
Field-specific reporting
Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
In general, no statistical methods were used to predetermine sample size. For the animal experiments, sample size was determined based on previous experience with intraperitoneal models of ovarian cancer and literature reports. For human samples, samples were collected until we felt the sample size was sufficient to give reliable estimates. For cell and biochemical data, we aimed to collect data from three biological replicates when possible.
Data exclusions No data were excluded from analysis.
Replication
Results were confirmed in at least three biological replicates for each experiment unless otherwise stated.
Randomization Samples/mice/human subjects were not randomized. Controlling for covariates was unnecessary for the human samples as all comparisons were between paired tumor/normal samples collected from the same patient. We did not control for covariates in the animal experiments because all animals were the same age and sex and were purchased from the same supplier.
Blinding
For the animal experiments, investigators were blinded to group allocation during intraperitoneal injections and when assessing outcome. For the other experiments on human samples and cell lines, blinding was not performed due to feasibility.
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